Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6NC | ISIN: US6827361030 | Ticker-Symbol: ON40
Siehe auch ONO PHARMACEUTICAL CO LTD
München
27.06.25 | 08:09
3,220 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
JAPAN
1-Jahres-Chart
ONO PHARMACEUTICAL CO LTD ADR Chart 1 Jahr
5-Tage-Chart
ONO PHARMACEUTICAL CO LTD ADR 5-Tage-Chart

Aktuelle News zur ONO PHARMACEUTICAL CO LTD ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoVertex and Ono Pharmaceutical form exclusive alliance for Povetacicept in Japan and South Korea16
11.06.LigaChem Biosciences Secures 3rd Milestone Payment from Ono Pharmaceutical4
28.05.Merck KGaA shares phase 3 rare tumor data ahead of showdown with Daiichi and Ono26
ONO PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln
08.05.Ono Pharmaceutical reports FY results10
29.04.Ono Pharma lays off 83 staffers at Cambridge site6
12.03.Ono earmarks $940m to gain rare blood cancer therapy from Ionis8
12.03.Ono pays $280M to license Ionis rare disease drug4
12.03.Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal2
12.03.Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono6
12.03.Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer4
04.03.DelveInsight Business Research, LLP: Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight787On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places...
► Artikel lesen
04.03.DelveInsight Business Research, LLP: Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight879On February 14, 2025, Ono Pharmaceuticals secured FDA approval for vimseltinib, a therapy for tenosynovial giant cell tumor (TGCT), which will be marketed as ROMVIMZA. This approval places...
► Artikel lesen
18.02.Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor8
17.02.Ono's TGCT therapy wins FDA approval, challenging Daiichi Sankyo23
17.02.Ono poised to join Daiichi in TGCT market after FDA nod7
03.02.Ono Pharmaceutical GAAP EPS of ¥162.87, revenue of ¥374.56B; reaffirms FY outlolok21
09.11.24Fate Therapeutics, Inc.: Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual ...336Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows Favorable...
► Artikel lesen
07.10.24Kinaxis Inc.: Kinaxis unterstützt das Lieferkettenmanagement von Ono Pharmaceutical505Kinaxis stellt Plattform für die End-to-End-Lieferkettenorchestrierung zur Unterstützung des weiteren globalen Wachstums von Ono Pharmaceutical bereit Kinaxis Inc. (TSX:KXS), ein Weltmarktführer...
► Artikel lesen
12.09.24Turbine Achieves Key Milestone in Collaboration with Ono Pharmaceutical513- Turbine has successfully completed the first phase of its oncology target identification and validation collaboration with Ono - Ono's selection of multiple targets identified using Turbine's...
► Artikel lesen
31.07.24EQS-News: Systasy Bioscience GmbH: Systasy Bioscience Announces Collaboration Agreement with Ono Pharmaceutical467EQS-News: Systasy Bioscience GmbH / Key word(s): Agreement Systasy Bioscience Announces Collaboration Agreement with Ono Pharmaceutical 31.07.2024 / 09:00 CET/CEST The...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1